Psychiatric Times, July 2007 A recently published study examined the impact of publicity regarding the pediatric suicidality data on the prescribing practices of physicians in the United States. The researchers focused on the period from June 2000 to March 2005. Major public events during that time included the FDA Public Health Advisory (Oct. 2003) on the occurrence of suicidality in clinical trials examining antidepressants in the treatment of children and adolescents with major depression; the FDA hearing (Feb. 2004) to review data regarding suicidality from these trials; and the FDA Public Health Advisory (March 2004) that asked antidepressant manufacturers to include a warning on the potential for suicidality and the importance of monitoring pediatric patients. Author is Dr. Karen Wagner, the Marie B. Gale Centennial Professor and vice chair in the department of psychiatry at the University of Texas Medical Branch in Galveston. Dr. Wagner is also behavioral sciences and director of child and adolescent psychiatry at UTMB.